A cancer arising from the liver cells (hepatocytes). Liver damage, manifested by cirrhosis (scarring), is a primary risk factor for liver cancer. Cirrhosis may be caused by viral hepatitis, primarily hepatitis B and C, alcohol abuse, hemochromatosis, certain autoimmune diseases of the liver, and other diseases that result in chronic inflammation of the liver.
Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136:E359-86; Ferlay J et al. Global Cancer Statistics. Ca Cancer J Clin 2011, 61:69–90; Siegel R et al. Cancer Statistics, 2017. Ca Cancer J Clin 2017, 67:7–30; Siegel R et al. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev. 2012, 21:411-416; McGlynn K et al. The Global Epidemiology of Hepatocellular Carcinoma, Present and Future Clin Liver Dis. 2011,15,223-x
The sixth most common cancer worldwide
749,000 new cases/year
In 2017, US estimated new cases for liver cancer is 40.710
Third cause of cancer related death worldwide
Accounts for 7% of all cancers worldwide
40% of them have poor liver function – not eligible for standard treatment
50% are diagnosed with advanced disease – incurable disease
Systemic treatment in patients with advanced disease cause quality of life deterioration
HCC treatment limitations
Treatment costs limit the access to new agents.
90% of patients are diagnosed with advanced disease and less then 50% have a treatment option.
Best systemic treatment will extent median survival by less then 4 month.
It is associated with poor liver function (cirrhosis) in 85% of the cases.
40% of patients are not fit enough for standard treatment.
Future targeted treatment programs
cases diagnosed 99% five years survival
cases diagnosed 90% five years survival
cases diagnosed 8% five years survival
cases diagnosed 5% five years survival
cases diagnosed 24% five years survival
cases diagnosed 47% five years survival
cases diagnosed 31% five years survival
from Globocan 2012 and Globocan Incidence 2012
This new medical device has not yet received regulatory approval and is not available for commercial distribution.
New Hampshire, USA
35 Main Street, Suite 208
+1 603 310-5044
São Paulo, Brasil
Rua Barata Ribeiro, 398 cj.22
São Paulo, SP